- Like-for-like sales growth: +7.1%
- Adjusted operating profit: +9%
- Net operational profit after minority interests*: € 908.4 m, +14.9%
Mr Lindsay Owen-Jones, Chairman and Chief Executive Officer of LÂ’OrÃ©al commented : These results, achieved in an extremely difficult environment, confirm LÂ’OrÃ©alÂ’s growth momentum and the improvement of operating margins. Although they cannot be directly extrapolated for the year as a whole, they permit us to confirm with renewed confidence our stated goal of double-digit earnings growth.
Innovation is the key to growthThe group's consolidated sales at 30th June 2003 amounted to € 7.14 billion. This represents a growth of +7.1%, compared with the 1st half of 2002, like-for-like (i.e. on an identical structural and exchange rate basis), and Â–3.2% based on consolidated figures.
Supported by innovations from the research laboratories, a large number of initiatives ensured growth for the group's core brands. Overall, LÂ’OrÃ©al achieved further major market share gains.
- The Professional Products Division achieved +8.8% growth in the first half, a much higher figure than its main competitors. The Division took new initiatives in all business segments, particularly in colourants with the launch of Luo (a new translucid colourant) and Equa (a formula developed specifically for the needs of the Japanese market).
- The Consumer Products Division achieved +9.3% like-for-like growth, well ahead of the growth rate for mass market products. This growth can be attributed in particular to the launch of innovative products such as Couleur Experte colourants and Double Extension mascara.
- The Luxury Products Division, operating in markets which are more sensitive to the economic slowdown and the reduction in air travel, managed to maintain growth of +0.2%. This performance comes from the success of new products such as the RÃ©solution facial skincare from LancÃ´me, a brand which at the end of 2002 became the worldÂ’s number one in the selective retailing channel. In perfumes, the successful European launch of Polo Blue by Ralph Lauren has confirmed the excellent results achieved in the United States.
- The Active Cosmetics Department continued its international roll-out, while improving its market shares in Europe. It thus achieved a growth rate of +10.9%, in line with the figure for the 1st half of 2002. This was boosted especially by the successful Myokine facial skincare from Vichy, and the skin redensifier Inneov FermetÃ© launched in five European countries, heralding the group's first move into the cosmetic nutritional supplement market.
- Dermatology (1) achieved sales of € 139 million, representing like-for-like growth of +7%.
Galderma performed well on the acne and rosacea markets. In geographic terms, Galderma continued to achieve sustained growth in North America and made strong advances in Latin America (Brazil +28%, Mexico +22%) and Asia (South Korea +23%).
Like-for-like sales growth
(1) Group share, i.e. 50%
|1st half 2003|
|€ millions||Like-for-like growth
|Professional Products||979||+ 8.8 %|
|Consumer Products||3,951||+ 9.3 %|
|Luxury Products||1,575||+ 0.2 %|
|Active Cosmetics||429||+ 10.9 %|
|Cosmetics total||6,991||+ 7.1 %|
|Western Europe||3,834||+ 5.3 %|
|North America||1,873||+ 6.1 %|
|Rest of the World||1,284||+ 14.6 %|
|Cosmetics total||6,991||+ 7.1 %|
|Dermatology(1)||139||+ 7.0 %|
|Group total||7,136||+ 7.1 %|
Substantial worldwide development
- The strong growth trend in Western Europe continued at +5.3%, in line with the rate achieved over the last 10 years. This was driven by rapid increases in several countries, particularly in the United Kingdom (+17%) and Spain (+12%).
- In North America, where cosmetics markets slowed, the group continued to win market share, achieving +6.1% like-for-like growth. This growth rate reflects in particular the extremely promising start made by Garnier's Fructis shampoo. The dynamism of all the Professional Products Division's brands Â– KÃ©rastase, Redken, Matrix and L'OrÃ©al Professionnel Â– is also worth noting.
- In the new markets, sales growth continued at an extremely high level (+14.6%).
- Despite the SARS epidemic, several Asian countries achieved very encouraging growth rates, particularly Taiwan and China, where first half sales increased by +61%.
- In Latin America, despite the difficulties, a high growth rate was achieved (+16%). L'OrÃ©al has made further breakthroughs in Brazil (+26%) and succeeded in turning round its Argentinean subsidiary (+38.3%).
- Growth was very strong in Eastern Europe (+25%), particularly in the Russian Federation, where sales increased by +38% following two years of extremely rapid growth, and in Hungary (+18%).
- Moreover, further breakthroughs were made in Australia (+19%) and in the Indian market (+34%).
Strong earnings growthAdjusted operating profit, i.e. including exchange gains and losses, advanced by +9% to € 1,129.1 million. It represented 15.8% of consolidated sales, compared with 14.1% at 30th June 2002, and 12.9% for 2002 as a whole.
This very marked improvement in margins comes from the good level of sales, the control of production costs, the scheduling of advertising and promotional expenses, and the careful management of exchange rate risks.
These figures reflect a significant improvement in operating margins, although it is not possible to extrapolate from them for the year as a whole.
Thanks to the reduction in debt and lower interest rates, net financial charges amounted to € 48.1 million, compared with € 66.3 million at 30th June 2002.
|Adjusted operating profit by branch|
|At 30th June 2002||At 30th June 2003||As % of sales|
|Cosmetics||€ 1,007.5m||€ 1,100.0m||15.7%|
|Dermatology (1)||€ 23.7m||€25.7m||18.5%|
|Growth = +9%|
|(1) Group share, i.e. 50%.|
As a result, the pre-tax profit of the fully consolidated companies amounted to € 1,080.9 million, up by +11.5%.
Corporate income tax at group level was € 357.7 million, up by +6.5%.
The net operational profit of the fully consolidated companies was thus € 723.2 million, up by +14.1%.
Excellent contribution from SANOFI-SYNTHELABOThe group share of the net profit of equity affiliates amounted to € 190.5 million. This consists of the group's share of the net profit of SANOFI-SYNTHELABO, which increased by +17.7%.
L'OrÃ©al's net operational profit after minority interests amounted to € 908.4 million, up by +14.9%.
|Main first-half indicators|
|At 30th June 2002||At 30th June 2003||Growth|
||7,371.3||7,136.8||- 3.2 %|
|Operating profit||1,017.0||1,037.2||+ 2.0 %|
|Adjusted operating profit(2)||1,036.1||1,129.1||+ 9.0 %|
|Pre-tax profit of fully consolidated companies||969.8||1,080.9||+ 11.5 %|
|Net operational profit of fully consolidated companies||633.9||723.2||+ 14.1 %|
|Group share of net operational profit of equity affiliates||161.9||190.5||+ 17.7 %|
|Net operational profit*||795.8||913.7||+ 14.8 %|
|Net book profit(3)||718.7||788.7||+ 9.7 %|
|Net operational profit after minority interests||790.6||908.4||+ 14.9 %|
|(2) Operating profit including exchange gains and losses.
(3) The net book profit after minority interests amounted to € 783.4 million, up by +9.8%, after € 91.1 million
of charges to provisions for treasury shares.
|*"Net operational profit " consists of the profit after tax of the fully consolidated companies and includes the group share of the net profit of equity affiliates. It does not include charges to/reversals of provisions for treasury shares, gains and losses on disposals of fixed assets, restructuring costs and amortisation of goodwill. This is the most significant measure of the group's recurrent performance, and has, without any change, for many years, been adopted by L'Oréal as the basis for calculating net earnings per share. It has also been adopted by the very great majority of financial observers.|